Exploratory data from KEYNOTE-B15 showed enfortumab vedotin/pembrolizumab improved ctDNA clearance in cisplatin-eligible MIBC #blcsm #oncology
Check out the findings presented at @myESMO #ESMO26: https://www.onclive.com/view/keynote-b15-ctdna-analysis-perioperative-ev-pembrolizumab-higher-ctdna-clearance-mibc
269 浏览 · 3 赞 · 2 转发 · 0 回复
ctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin
https://esmocongress.esmo.org- **标题 / Title：** Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
https://esmocongress.esmo.org来源：OncLive.com · x.com